Pantozol Control (Pantoprazole)

Pantoprazole, the active ingredient in Pantozol Control, is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid secretion and is prescribed for conditions such as gastro‑oesophageal reflux disease, ulcer disease and related acid‑related disorders.

GNH USA supplies Pantozol Control as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole is a proton pump inhibitor used to manage acid‑related gastrointestinal conditions.

- Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining. - Erosive oesophagitis: accelerates mucosal healing and reduces recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid production. - NSAID‑induced ulcer disease: aids ulcer healing and prevents recurrence. - Helicobacter pylori eradication (as part of combination therapy): enhances eradication rates when used with antibiotics.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: usually transient. - Nausea: may accompany initial therapy. - Abdominal pain: occasional discomfort. - Flatulence: excess gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk. - Severe allergic reactions: rash, angioedema, anaphylaxis. - Low serum magnesium (hypomagnesemia): may cause muscle cramps or arrhythmia. - Liver enzyme elevation: monitor hepatic function. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: rare but life‑threatening skin reactions. - Pancreatitis: acute inflammation of the pancreas.

When prescribing Pantoprazole, consider the following precautions.

- Renal function assessment: adjust use in severe renal impairment. - Monitor magnesium levels: long‑term therapy may lead to hypomagnesemia. - Hepatic impairment: use with caution in patients with liver disease. - Rebound acid hypersecretion: avoid abrupt discontinuation after prolonged use. - Review concomitant medications: assess for potential interactions. - Store at room temperature: keep in the original pack, protect from moisture.

Pantoprazole may interact with several medicines; awareness helps prevent reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect. - Atazanavir: decreased absorption, loss of antiviral activity. - HIV protease inhibitors (e.g., ritonavir): lowered plasma concentrations. - Methotrexate: increased toxicity risk. - Digoxin: may increase serum levels.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR. - Phenytoin: reduced phenytoin levels. - Fluconazole: may increase pantoprazole exposure. - Rifampin: may decrease pantoprazole effectiveness. - St. John’s wort: possible reduction in drug exposure.